For pharma and biopharma business developers, the partnering event concept of "Continuous Business Development" has proven to be more productive than once-a-year partnering events. More
With deals increasing in terms of number and value, partnering at early stage development is now an integral component of pharmaceutical and biotech business strategy. Pharmalicensing has revised and updated its successful Early Stage report More
Research into neurodegenerative disease at the Institute of Psychiatry has resulted in the development of a series of biomarkers, or tests, for Alzheimer’s disease. More
The Wellcome Trust Limited and The Institute of Cancer Research announced a new alliance with GlaxoSmithKline to discover, develop and commercialize novel small molecule inhibitors of B-RAF for use as anti-cancer agent, More
The internationally renowned scientific journal "Nature" publishes in today's issue an article about plectasin, which is a great acknowledgement of the work carried out within the research project. More
Proximagen, a King’s College London spin-out company focusing on neurodegenerative diseases, has raised £50 million in one of the largest biotech fundraisings in the UK in the past ten years. More
All rights reserved. Terms and Conditions | Contact us
